Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma

Background Although most studies of anticancer T-cell immunity focus on αβ T cells, γδ T cells are attracting increasing attention due to their involvement in antitumor immune responses in various cancer entities, including melanoma. While immune checkpoint blockade (ICB) using the antagonistic prog...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Herold, Nicola (VerfasserIn) , Bochem, Jonas (VerfasserIn) , Leyens, Johanna (VerfasserIn) , Wingerter, Svenja (VerfasserIn) , Forchhammer, Stephan (VerfasserIn) , Spreuer, Janine (VerfasserIn) , Deseke, Malte (VerfasserIn) , Yurttas, Can (VerfasserIn) , Nocerino, Paola (VerfasserIn) , Reis, Rita Antunes dos (VerfasserIn) , Amaral, Teresa (VerfasserIn) , Wagner, Nikolaus B. (VerfasserIn) , Thiel, Karolin (VerfasserIn) , Soffel, Daniel (VerfasserIn) , Bieber, Kristin (VerfasserIn) , Terheyden, Patrick (VerfasserIn) , Wesch, Daniela (VerfasserIn) , Oberg, Hans-Heinrich (VerfasserIn) , Sebens, Susanne (VerfasserIn) , Claassen, Manfred (VerfasserIn) , Königsrainer, Alfred (VerfasserIn) , Garbe, Claus (VerfasserIn) , Pawelec, Graham (VerfasserIn) , Meier, Friedegund (VerfasserIn) , Löffler, Markus W. (VerfasserIn) , Weide, Benjamin (VerfasserIn) , Prinz, Immo (VerfasserIn) , Ravens, Sarina (VerfasserIn) , Kordasti, Shahram (VerfasserIn) , Eigentler, Thomas (VerfasserIn) , Wistuba-Hamprecht, Kilian (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: January 2026
In: Journal for ImmunoTherapy of Cancer
Year: 2026, Jahrgang: 14, Heft: 1, Pages: 1-15
ISSN:2051-1426
DOI:10.1136/jitc-2024-011224
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1136/jitc-2024-011224
Verlag, kostenfrei, Volltext: https://jitc.bmj.com/content/14/1/e011224
Volltext
Verfasserangaben:Nicola Herold, Jonas Bochem, Johanna Leyens, Svenja Wingerter, Stephan Forchhammer, Janine Spreuer, Malte Deseke, Can Yurttas, Paola Nocerino, Rita Antunes dos Reis, Teresa Amaral, Nikolaus B. Wagner, Karolin Thiel, Daniel Soffel, Kristin Bieber, Patrick Terheyden, Daniela Wesch, Hans-Heinrich Oberg, Susanne Sebens, Manfred Claassen, Alfred Königsrainer, Claus Garbe, Graham Pawelec, Friedegund Meier, Markus W. Löffler, Benjamin Weide, Immo Prinz, Sarina Ravens, Shahram Kordasti, Thomas Eigentler, Kilian Wistuba-Hamprecht
Beschreibung
Zusammenfassung:Background Although most studies of anticancer T-cell immunity focus on αβ T cells, γδ T cells are attracting increasing attention due to their involvement in antitumor immune responses in various cancer entities, including melanoma. While immune checkpoint blockade (ICB) using the antagonistic programmed cell death protein 1 (PD-1) antibodies nivolumab and pembrolizumab significantly improved the survival of patients with melanoma with distant metastasis, prognosis remains poor. PD-1 is not only expressed by αβ T cells but also by γδ T cells, making this numerically minor population of unconventional T cells, whose role in melanoma is still elusive, a target of ICB.Methods Here, we present a detailed γδ T-cell profiling study in late-stage melanoma at single-cell level using mass and polychromatic flow cytometry, T-cell receptor repertoire analyses and immunohistochemistry.Results Our analyses link high frequencies of peripheral Vδ1 T cells before the start of anti-PD-1 therapy to a significantly reduced overall survival. In these patients, the Vδ1 compartment is dominated by a late-differentiated senescent-like phenotype that is presumably unresponsive to therapy. This phenotype is less prevalent at the tumor site and analysis of RNA sequencing data revealed that the abundance of Vδ1 T cells within the tumor was positively associated with survival.Conclusions Our study suggests that Vδ1 T cells are associated with clinical outcomes, with a responsive subset expanding under ICB in patients where such a response remains possible. The observed clinical effects may be supported by the infiltration of these cells into the tumor, where they contribute to cancer immunosurveillance.
Beschreibung:Online veröffentlicht: 20 January 2026
Gesehen am 12.02.2026
Beschreibung:Online Resource
ISSN:2051-1426
DOI:10.1136/jitc-2024-011224